Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Scholar Rock Holding Corp(SRRK)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SRRK
10/28/2026: SRRK (3-star) is currently NOT-A-BUY. Pass it for now.
Scholar Rock is a clinical-stage-turned-commercial biopharmaceutical company focused on developing therapies for rare neuromuscular diseases, most notably spinal muscular atrophy. Its main strength lies in its proprietary platform that selectively targets protein growth factors, resulting in its first FDA-approved product, Isembyld. The company's primary growth opportunity is the successful commercial launch of Isembyld and the potential extension of its technology into cardiometabolic indications. Risks include intense competition from established biopharma, high execution requirements for commercialization, and the ongoing need for capital. The stock may best suit growth-oriented investors looking for exposure to novel biotech innovation, provided they can tolerate significant volatility.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company's transition to a commercial-stage firm provides a clear growth catalyst centered on its newly approved SMA therapy. |
| Momentum investor | Strong fit while signal remains positive | Market attention following the launch of Isembyld makes this ticker a potential play for momentum-driven price action. |
| Value investor | Weak fit | The lack of consistent earnings and high clinical development risk make it unsuitable for traditional value-based strategies. |
| Dividend investor | Weak fit | Scholar Rock is a growth-stage biotech that does not pay dividends and focuses all capital on pipeline development and commercialization. |
| Low-risk investor | Weak fit | The high volatility inherent in clinical-stage biopharma renders this stock unsuitable for risk-averse portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks often experience extreme price swings based on clinical data, regulatory decisions, and market sentiment. |
| Valuation risk | Medium / high | The stock price reflects high growth expectations that may be disrupted if the commercial launch of Isembyld fails to meet targets. |
| Competition risk (Rare Disease/SMA competition) | High | Established players with massive resources have significant influence over the standard of care in the rare disease market. |
| Business quality | Medium | The business is transitioning, and its long-term commercial execution remains to be proven at scale. |
| Dividend income | Low / none | There is no dividend income as the company is focused on reinvestment. |
| Execution risk | Medium / high | The company must successfully navigate the complex logistics of a commercial product launch for the first time. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 53.94% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.27B USD | Price to earnings Ratio - | 1Y Target Price 70.44 |
Price to earnings Ratio - | 1Y Target Price 70.44 | ||
Volume (30-day avg) 2.0M shares | Beta 0.62 | 52 Weeks Range 27.07 - 61.76 | Updated Date 10/28/2026 |
52 Weeks Range 27.07 - 61.76 | Updated Date 10/28/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.32 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Revenue | Sales of its FDA-approved lead asset, Isembyld (apitegromab), for spinal muscular atrophy. | The company's primary potential revenue source is now the commercial sale of its breakthrough muscle-targeted drug. |
| Collaboration and Licensing | Milestone payments and royalties from partnerships for its growth factor-targeting platform. | The company may also generate cash through deals with larger pharma partners to develop parts of its pipeline. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4.89B | Price to Sales(TTM) 13.14 |
Enterprise Value 4.89B | Price to Sales(TTM) 13.14 | ||
Enterprise Value to Revenue 8.22 | Enterprise Value to EBITDA -2.08 | Shares Outstanding 121.79M | Shares Floating 104.09M |
Shares Outstanding 121.79M | Shares Floating 104.09M | ||
Percent Insiders 0.73 | Percent Institutions 117.47 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.